Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients
Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Y, Tereshkov P, Shapovalov Y, Konnov V, Tsybikov N · 2021 · Advances in Gerontology. 11(4):368–376
Reported findings and study design
In-hospital mortality was 7/36 (19.4%) with Thymalin versus 18/44 (40.9%) with saline placebo (p=0.039). Clinical improvement was 29/36 (80.5%) versus 26/44 (59%; p=0.039).
Dose, route and schedule
Thymalin 10 mg intramuscularly daily for 10 days versus 2 mL saline, both alongside standard care. Historical study methods, not treatment advice.
Protocol source ↗ · Original full-text methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| In-hospital mortality | 7/36 (19.4%) versus 18/44 (40.9%) | p=0.039 |
| Clinical improvement | 29/36 (80.5%) versus 26/44 (59%) | p=0.039 |
| Time to clinical improvement | 8.63 ± 0.68 versus 7.61 ± 0.93 days | p=0.41 |
| Day-14 CT improvement | 11/36 (30.5%) versus 10/44 (22.7%) | p=0.43 |
| Lymphocyte recovery | 24/36 (66.6%) versus 19/44 (43.18%) | p=0.037 |
| Time to lymphocyte recovery | 7.36 ± 0.56 versus 10.78 ± 0.53 days | p=0.002 |
Single-center, single-blind study using early-pandemic care; findings require confirmation under contemporary treatment. CT improvement and time to clinical improvement did not differ significantly.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Single-center, single-blind study using early-pandemic care; findings require confirmation under contemporary treatment.
- CT improvement and time to clinical improvement did not differ significantly.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Full-text methods and clinical outcome table checked
Source access and review scope
Primary full-text methods and Table 3 checked on PMC; no independent reanalysis.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Original journal report
Citation and original source
Original source: Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Y, Tereshkov P, Shapovalov Y, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients Advances in Gerontology. 11(4):368–376 2021.
Molekul research summary: https://molekul.io/research/placebo-thymalin-covid-2021. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry